OUR FOCUS:

ENABLING safer, simpler and more effective drug delivery

IMPROVING outcomes through innovation, timely and efficient diagnostics

PROVIDING tools and technologies that enhance the understanding of the cell, cellular diagnostics and cell therapy

ENHANCING disease management in diabetes, women’s health and cancer, and infection control

ADVANCING clinical, laboratory and research practices in emerging markets

IN 2015, BD welcomed CareFusion and its products into the BD family of solutions.

For more information on BD, please visit www.bd.com.

OUR PURPOSE:

Advancing the world of health

BD is a leading medical technology company that partners with customers and stakeholders to address many of the world’s most pressing and evolving health needs.

45,000 ASSOCIATES SERVING MORE THAN 190 COUNTRIES

OVER 200,000 ASSOCIATES SERVING 250+ COUNTRIES

PRINTING INFORMATION*

BD saved the following resources by using 25,736 pounds of Reincarnation Silk 100, made with an average of 100% recycled fiber and an average of 100% post-consumer waste. It is designated Ancient Forest Friendly™ and manufactured with electricity that is offset with Green-e® certified renewable energy certificates.

For information about BD’s Sustainability Program and our 2020 Sustainability Goals, please visit www.bd.com/sustainability2014.

* Source: Calculations based on research by Environmental Defense Fund and other members of the Paper Task Force.
Our focus:

Enabling safer, simpler and more effective drug delivery

Improving outcomes through more accurate, timely and efficient diagnostics

Providing tools and technologies to the research community that facilitate the understanding of the cell, cellular diagnostics and cell therapy

Enhancing disease management in diabetes, women’s health and cancer, and infection control

Advancing clinical, laboratory and research practices in emerging markets

In 2015, BD welcomed CareFusion and its products into the BD family of solutions. For more information on BD, please visit www.bd.com.

Our purpose:

Advancing the world of health

BD is a leading medical technology company that partners with customers and stakeholders to address many of the world’s most pressing and evolving health needs.
TO OUR SHAREHOLDERS:

By all measures, fiscal 2015 was a historic year for BD, unlike any other in our 118-year history. It has been my distinct pleasure and privilege to be at the helm as we evolve into a bigger, better and bolder company — a “New BD” that will be stronger and more relevant than ever before.

During this transformative year, we repositioned BD as a global leader in medication management and healthcare safety solutions with the $12 billion acquisition of CareFusion. Combining with CareFusion advances our strategy to deliver end-to-end solutions that increase efficiency, reduce medication errors and improve both healthcare worker and patient safety across all healthcare settings. At the same time, we entered the genomics space with the acquisitions of GenCell Biosystems and Cellular Research combined with our more than 30 years of experience in cell-sorting technologies. We’re seeking to improve the sample management process in the fast-growing arena of next generation sequencing (NGS) by helping customers increase workflow efficiency, improve outcomes and reduce costs.

The underlying principle that guided our CareFusion integration efforts was as simple as it was ambitious: to focus our work on creating a new and better healthcare company. Our teams were charged with more than just identifying synergy opportunities; they also had to challenge themselves to transform the organization and how we work. We made integrating cultures a top priority, rearticulating our company purpose to reflect our leadership role in Advancing the world of health. We also refreshed our brand identity and introduced a new set of value statements to reflect the strengths and beliefs of both legacy organizations.

Our merger doubled the size of the BD Medical segment during the year, and as a combined company, we became a leader in the $20 billion medication management space. With this strong foundation in place, we’ve been able to make significant progress integrating CareFusion and BD. We are creating end-to-end solutions across the care continuum — from the hospital, to alternate care and retail settings, to the home — to improve healthcare efficiency, quality...
The New BD — structured to serve customers with unique solutions

**BD MEDICAL**

**Diabetes Care**
- Medication Management Solutions
- Medication and Procedural Solutions
- Pharmaceutical Systems
- Respiratory Solutions

**INNOVATIVE OFFERINGS**
- ChloraPrep® Skin Antiseptic
- BD Eclipse™ Needle
- BD Intelect™ Medication Management System
- BD Care™ Medication Workflow Solution
- Pye Medication™ IV System
- Alaris™ System
- BD Naive™ Iven Peripherals
- BD AutoShield Duo™ Pen Needle
- BD Hypo™ Glass Syringes
- AHS™ Vials

**REDUCE**
- the speed of infections

**ENHANCE**
- diabetes treatment

**ADVANCE**
- delivery

**IMPROVE**
- respiratory care and surgical procedures

**PROVIDE**
- effective and safe medication management

**SERVING CUSTOMERS**
- Hospitals and health systems
- Physicians
- Government and public health agencies
- Healthcare workers
- Retail pharmacies
- Pharmaceutical and biotech companies
- Consumers

**BD LIFE SCIENCES**

**Biosciences**
- Diagnostic Systems
- Preanalytical Systems

**INNOVATIVE OFFERINGS**
- BD Vacutainer® Solid-Section Blood Collection Set
- BD Vacutainer® Blood Collection Tube
- BD Vertacer™ Laboratory Automation
- BD Veritor™ System
- BD MX™ System
- BD Kiestra™ Laboratory Automation System
- BD Reveal™ Cytometer
- BD Luminex® x20 Cytometer

**ADVANCE**
- the science and applications associated with cellular analytics

**IMPROVE**
- test efficiency and outcomes
- from sample collection to diagnostic result

**ENHANCE**
- infectious disease diagnosis and management

**DELIVERING OUTCOMES**
- Research, clinical, industrial and reference laboratories
- Blood banks
- Hospitals and clinics
- Alternative site healthcare
- Public health agencies
- Academic and government institutions
- Pharmaceutical and biotech companies

**SERVING CUSTOMERS**
- Research, clinic, industrial and reference laboratories
- Blood banks
- Hospitals and clinics
- Alternative site healthcare
- Public health agencies
- Academic and government institutions
- Pharmaceutical and biotech companies

**PRINTING INFORMATION**

BD saved the following resources by using 25,736 pounds of Reincarnation Silk 100, made with an average of 100% recycled fiber and an average of 100% post-consumer waste. It is designated Ancient Forest Friendly™ and manufactured with electricity that is offset with Green-e® certified renewable energy credits. For information about BD’s Sustainability Program and our 2020 Sustainability Goals, please visit www.bd.com/sustainability2014.

*Source Calculations based on research by Environmental Defense Fund and other members of the Paper Task Force.*
The New BD — structured to serve customers with unique solutions

**BD MEDICAL**
- Diabetes Care
- Medication Management Solutions
- Medication and Procedural Solutions
- Pharmaceutical Systems
- Respiratory Solutions

**INNOVATIVE OFFERINGS**
- **ChloraPrep® Skin Antiseptic**
- **BD Eclipse™ Needle**
- **BD Eclipse™ Medication Management System**
- **BD Care™ Medication Workflow Solution**
- **Pyte Medication® 15 System**
- **Alaria™ System**
- **BD Nasea™ veni Perineedle**
- **BD AutoShield Duo™ Retractable**
- **BD Hypion™ Glass Prefilled Syringes**
- **AVIA™ Ventilator**
- **REDUCE** the spread of infection
- **ENHANCE** diabetes treatment
- **ADVANCE** drug delivery
- **IMPROVE** respiratory care and surgical procedures
- **PROVIDE** effective and safe medication management

**DELIVERING OUTCOMES**
- Hospitals and clinics
- Physicians
- Government and public health agencies
- Healthcare workers
- Retail pharmacies
- Pharmaceutical and biotech companies
- Consumers

**BD LIFE SCIENCES**
- Biosciences
- Diagnostic Systems
- Preanalytical Systems

**INNOVATIVE OFFERINGS**
- **BD Vacutainer® Push Button Blood Collection Set**
- **BD Vacutainer® Blood Collection Tube**
- **BD Veritor™ Laboratory Automation**
- **BD Veritor™ System**
- **BD MAX™ System**
- **BD FACSPresto™ Near-Patient CD4 Counter**
- **BD Horizon Brilliant™ BD LSRFortessa™ X-20 Cell Analyzer**
- **ADVANCE** the science and applications associated with cellular analytics
- **IMPROVE** test efficiency and outcomes from sample collection to diagnostic result
- **ENHANCE** infectious disease diagnosis and management

**DELIVERING OUTCOMES**
- Research, clinical, reference and reference laboratories
- Blood banks
- Hospitals and clinics
- Alternative site healthcare
- Public health agencies
- Academics and government institutions
- Pharmaceutical and biotech companies

**SERVING CUSTOMERS**
- Businesses
  - Diabetes Care
  - Medication Management Solutions
  - Medication and Procedural Solutions
  - Pharmaceutical Systems
  - Respiratory Solutions

**PRINTING INFORMATION**
- BD saved the following resources by using 25,736 pounds of Reincarnation Silk 100, made with an average of 100% recycled fiber and an average of 100% post-consumer waste. It is designated Ancient Forest Friendly™ and manufactured with electricity that is offset with Green-e® certified renewable energy certificates.

For information about BD’s Sustainability Program and our 2020 Sustainability Goals, please visit **www.bd.com/sustainability2014**.
and outcomes. During the year, we also advanced our chronic disease management strategy, expanding our impact in diabetes management beyond products for insulin injection.

While much of the spotlight this past year was on the BD Medical segment as a result of the CareFusion acquisition, we also made strategic investments in our BD Life Sciences segment, which remains an important growth driver for BD as we aim to improve lab efficiency and outcomes from sample to diagnostic result. We believe our GenCell and Cellular Research portfolio additions—in combination with our robust innovation pipeline and our experience developing research-to-clinical applications—puts us well on the path toward “democratizing” NGS by improving workflow efficiency and outcomes and driving down costs in the sample management process.

With our progress in fiscal 2015 and our growth strategies for fiscal 2016 and beyond, we are very well positioned to become a more customer-centric provider of world-class, quality, innovative healthcare products and solutions—a company focused on increasing access, improving outcomes, mitigating healthcare system cost pressures and protecting patients and healthcare workers. While we continue to expand our leadership and relevance in the spaces, care settings and geographies that we have served so well for so long, we are also beginning to extend into emerging areas—including digital health and single cell genomics, and adjacent care settings across the patient care continuum—to ensure we are well aligned as our dynamic industry continues to evolve.

BD’s global footprint, scale and infrastructure creates even more opportunity for our businesses around the world.

### Revenue by Region

<table>
<thead>
<tr>
<th>Region</th>
<th>Revenue (billions of dollars)</th>
</tr>
</thead>
<tbody>
<tr>
<td>United States</td>
<td>$5.1</td>
</tr>
<tr>
<td>Europe</td>
<td>$2.4</td>
</tr>
<tr>
<td>Greater Asia</td>
<td>$1.5</td>
</tr>
<tr>
<td>Other</td>
<td>$1.2</td>
</tr>
</tbody>
</table>

(1) Values in this exhibit reflect rounded numbers.
(2) Other comprises Canada, Latin America, and EMA (which includes the Commonwealth of Independent States, Middle East and Africa).
Overall, our financial results for fiscal 2015 were very strong, closing out a historic year for BD. We exceeded $10 billion in revenues, driven primarily by the addition of the CareFusion portfolio during the second half of the fiscal year and solid performance in our core businesses. Including the results of CareFusion in both the current- and prior-year periods, our revenues increased in line with our long-term goal of delivering top-line growth in the mid-single digits annually.

These results also reflected the benefit of our diverse geographic and product portfolio, as we saw solid contributions from both the BD Medical and BD Life Sciences segments as well as our global markets. We delivered strong growth in the U.S. region, and because CareFusion revenues are predominantly derived from developed markets, we will continue to see more balanced top-line contributions from the U.S. and international markets going forward. Although emerging markets will represent a lower percentage of overall company revenues, we continue to invest in these higher-growth areas and are working to create new growth opportunities for CareFusion products in these markets by leveraging the BD international infrastructure.

Our strong top-line growth carried through to the bottom line as our adjusted diluted earnings per share exceeded our guidance range for the year. This was due, in part, to merger-related cost savings. Through the tremendous work of our functional integration teams, we exceeded our internal cost-savings targets for the first year of the CareFusion merger. We now expect to deliver between $325 million and $350 million in cost savings.

Values in this exhibit reflect rounded numbers.
ADVANCING
MEDICATION MANAGEMENT

BD became the global leader in the $20 billion medication management industry with the acquisition of CareFusion. The new extended portfolio of products provides a complete end-to-end solution from pharmacy to patient.

Using the CAREFUSION SMARTWORKS PLATFORM as the communication backbone between our solutions and Health IT systems, BD offers a safer and more efficient way to procure, store, prep, track, dispense, administer and analyze medications across a health system and the entire continuum of care. The platform leverages innovative technologies including BD Cato™ Medication Workflow Solutions for safer and more efficient drug preparation, the Pyxis® ES system for enterprise medication dispensing, the Alaris® System for safe IV and advanced analytics that provide decision support and medication adherence capabilities.

savings by fiscal 2018, up from our earlier target of $250 million.

Further, we demonstrated a balanced approach to capital deployment in fiscal 2015. We paid off $1 billion in debt used to partially fund the CareFusion acquisition and increased our dividend for the 43rd consecutive year. We will balance the investments we make in organic and inorganic growth opportunities and efficiency improvements with our targeted leverage goals while increasing our dividend in line with long-term earnings growth. We believe the combination of our business and geographic diversity, our balanced capital allocation and focus on efficiency provides a long-term pathway toward sustainable, profitable growth.

DRIVING GROWTH THROUGH INNOVATION

BD continued to focus on innovation in fiscal 2015 to drive future financial performance and growth. The combined efforts of our internal teams and our external strategic partners and alliances helped us to build a pipeline of new, clinically differentiated products. During the year, we reinvested more than 6 percent of revenues in R&D, funding the development of new products that we believe will help us drive and sustain our growth over the long term. We entered the fiscal year with more products in our pipeline than ever before and expect to launch more than 15 new products in fiscal 2016 alone.

In recognition of our sustained efforts to create a culture of innovation, BD was honored by the Product Development and Management Association with its prestigious 2015 Outstanding Corporate...
ADVANCING GENOMICS AND LABORATORY PRODUCTIVITY

BD Life Sciences is entering the high-growth genomics area through internal developments combined with strategic acquisitions. Our differentiated platforms create a base to further grow our genomics offering, leaving BD well-positioned to add long-term value by providing researchers and clinicians leading technologies that are efficient, scalable, high quality and cost effective.

BD is launching its first dedicated solution specifically for single cell genomics applications with **BD FACSeq™ CELL SORTER**, a high-throughput cell sorter designed for single cell genomic studies, combined with **BD Precise™ ASSAYS** for single cell gene expression analysis. The combination enables thousands of cells to be analyzed accurately, quickly, easily and affordably. Understanding the genomic differences of individual cell types provides unique insights into disease characteristics that have the potential to identify new approaches for developing targeted therapies.

**Innovator Award.** This recognition validates our efforts over the past five years to improve the efficiency and effectiveness of our R&D programs and to transform our product development system, processes and approach to drive commercial excellence and better deliver on market and customer needs in alignment with our global growth strategies.

**PURSUING OUR PURPOSE**

While much is changing at BD, the core of who we are and what we stand for has not wavered. Our purpose—Advancing the world of health—highlights our expanded role as an industry leader and reinforces our commitment and ability to improve healthcare around the globe.

We will continue our track record of shared-value creation, seeking out opportunities to serve unmet societal needs through business models and initiatives that also contribute to our commercial success. We embrace the opportunity to make a meaningful difference in the lives of others and in the communities we call home. This year marked the 10th anniversary of the BD Volunteer Service Trip, a unique opportunity that pairs BD volunteers with selected healthcare organizations and programs that serve at-risk populations. Over the past decade, more than 110 volunteers have been deployed to 20 countries to share their compassion and expertise to help strengthen local healthcare services and improve the overall quality of life and health for the people they serve.

Such endeavors earned BD a spot on FORTUNE magazine’s first-ever “Change the World” list, which acknowledges companies that make a sizable impact on major social or environmental problems as part of their competitive strategy. For me, this recognition is a testament to the unique — and rewarding — opportunity our associates have as part of BD, where employees can fulfill their life’s work through their work life.

**CONCLUSION**

As we look forward, the prospects for the New BD are stronger than ever. Our diversified Medical and Life Sciences segments offer clinically differentiated products and innovative solutions that span discovery and delivery and
anticipate and address our customers’ and healthcare systems’ most pressing challenges. Our global footprint, scale and infrastructure create even more opportunity for BD to help increase healthcare access and improve outcomes. We are guided by a clear strategy grounded in customer needs, a renewed purpose, a strong commitment to our values and a refreshed brand identity that signals our transformation to a bigger, better, bolder BD is firmly underway.

There are many people who deserve thanks for this incredible year, especially the 45,000 associates around the world who are pulling together to create the New BD. Chief among them is Bill Kozy, our Executive Vice President and Chief Operating Officer, whom I want to thank for the exemplary work he and his team are doing to lead the successful integration of CareFusion and BD. After 41 years with BD, Bill has announced his retirement. He will stay with us through the end of March 2016 to ensure a successful transition of his integration duties to Chris Reidy, our Executive Vice President, Chief Financial Officer, and Chief Administrative Officer. Bill has demonstrated a relentless commitment to operational excellence to our customers and associates and has had a profound influence on us all. I want to express my gratitude for his leadership as well as my congratulations on his reaching this key milestone.

I also want to extend my personal thanks to two of our Board members — Henry Becton, Jr. and Edward DeGraan — who are retiring following the 2016 Annual Meeting. Ed is stepping down after 12 years of dedicated service, during which he provided valuable leadership to management and the Board in a number of areas. Henry has served on the Board since 1987 and is transitioning to the role of Director Emeritus following the 2016 Annual Meeting. His broad business background, coupled with his extensive personal knowledge of BD, has made him an invaluable resource to the company.

While I’m proud of the many accomplishments we achieved this past year, I’m more excited about the future — about the potential developing within BD, the opportunities to reshape and redefine our industry and the positive impact we can have Advancing the world of health.

I look forward to sharing this journey with you and want to thank you for your ongoing support and investment in BD.

Sincerely,

Vincent A. Forlenza
Chairman, Chief Executive Officer and President

2015 AWARDS, RECOGNITIONS AND AFFILIATIONS

Dow Jones Sustainability North America Index, since 2005
FORTUNE — “Change the World” List 2015
Center for Political Accountability — Top Leader in Disclosure and Accountability 2015
CEO Cancer Gold Standard™ Accreditation

Top Employers Africa 2015 — Top Employers Institute
Best Places for Women & Diverse Managers to Work — Diversity MBA
50 Out Front for Diversity Leadership
Work-Life Seal of Distinction — WorldatWork’s Alliance for Work-Life Progress®
FTSE4Good Index, since 2003

Practice Greenhealth — Champion for Change Environmental Excellence
U.S. EPA Green Power Leadership Award
U.S. EPA SmartWay® Transport Partner — Member
Windmade™ — Pioneer Company

*FORTUNE is a registered trademark of Time Inc. and is used under license. From FORTUNE Magazine © 2015 Time Inc. FORTUNE and Time Inc. are not affiliated with, and do not endorse products or services of, Licensee.
CORPORATE INFORMATION

ANNUAL MEETING
Tuesday, January 26, 2016 – 1:00 p.m.
Four Seasons Hotel New York
57 East 57th Street
New York, NY 10022
This annual report is not a solicitation of proxies.

TRANSFER AGENT AND REGISTRAR
Computershare Trust Company, N.A.
250 Royall Street
Canton, MA 02021
Phone: 1-877-498-8861
International: 1-781-575-2726
Internet: www.computershare.com

DIRECT STOCK PURCHASE PLAN
The Direct Stock Purchase Plan established through Computershare Trust Company, N.A., enhances the services provided to existing shareholders and facilitates initial investments in BD shares. Plan documentation and additional information may be obtained by calling Computershare Trust Company, N.A., at 1-877-498-8861, or by accessing the “Buy stock direct” feature located within the Investor Centre of Computershare’s website at www.computershare.com.

NYSE SYMBOL: BDX

INDEPENDENT AUDITORS
Ernst & Young LLP
5 Times Square
New York, NY 10036-6530
Phone: 1-212-773-3000
Internet: www.ey.com

SHAREHOLDER INFORMATION

At November 30, 2015, BD had 14,414 shareholders of record. BD's Statement of Corporate Governance Principles, BD’s Code of Conduct, the charters of BD’s Committees of the Board of Directors, BD’s reports and statements filed with or furnished to the Securities and Exchange Commission and other information are posted on BD’s website at www.bd.com/investors.

Shareholders may receive, without charge, printed copies of these documents, including BD’s 2015 Annual Report on Form 10-K, including the financial statements and related schedules, by contacting:

Investor Relations
BD
1 Becton Drive
Franklin Lakes, NJ 07417-1880
Phone: 1-800-284-6845
Internet: www.bd.com

The trademarks indicated by italics are property of Becton, Dickinson and Company, its subsidiaries or related companies.
©2015 BD
All other brands or logos represented herein are trademarks of their respective owners.

The graph below presents a comparison of cumulative total return to shareholders for the five-year period ended September 30, 2015, for BD, the S&P 500 Index and the S&P 500 Health Care Equipment Index.

Cumulative total return to shareholders is measured by dividing total dividends (assuming dividend reinvestment) plus per share price change for the period by the share price at the beginning of the measurement period. BD’s cumulative shareholder return is based on an investment of $100 on September 30, 2010, and is compared to the cumulative total return of the S&P 500 Index and the S&P 500 Health Care Equipment Index over the same period with a like amount invested.

Comparison of 5-year Cumulative Total Return Among Becton, Dickinson and Company, the S&P 500 Index, and the S&P 500 Health Care Equipment Index*

*Source: Thomson Reuters
CORPORATE OFFICERS

VINCENT A. FORLENZA
Chairman, Chief Executive Officer and President

PIERRE BOISIER
Executive Vice President and Chief Quality Officer

GARY M. COHEN
Executive Vice President and President — Global Health

ALEXANDRE CONROY
Executive Vice President and President — Europe, EMA and Americas

GARY DEFAZIO
Senior Vice President and Corporate Secretary

JOHN E. GALLAGHER
Senior Vice President, Corporate Finance, Treasurer and Controller

DAVID W. HIGHET
Senior Vice President, Chief Intellectual Property Counsel and Assistant Secretary

JEROME V. HURWITZ
Executive Vice President and Chief Human Resources Officer

WILLIAM A. KOZY
Executive Vice President and Chief Operating Officer

JAMES LIM
Executive Vice President and President — Greater Asia

RICHARD J. NAPLES
Executive Vice President and Chief Regulatory Officer

THOMAS POLEN
Executive Vice President and President — Medical Segment

CHRISTOPHER R. REIDY
Executive Vice President, Chief Financial Officer and Chief Administrative Officer

PATTI E. RUSSELL
Senior Vice President and Chief Ethics and Compliance Officer

ANTOINETTE F. SEGRETO
Senior Vice President — Taxes

NABIL SHABSHAB
Executive Vice President — Strategic Planning and Chief Marketing Officer

JEFFREY S. SHERMAN
Executive Vice President and General Counsel

STEPHEN SICHAK, JR.
Executive Vice President and Chief Integrated Supply Chain Officer

ELLEN R. STRAHLMAN, M.D.
Executive Vice President — Research and Development and Chief Medical Officer

LINDA THARBY
Executive Vice President and President — Life Sciences Segment

BOARD OF DIRECTORS

BASIL L. ANDERSON 1,2,4
Retired Vice Chairman — Staples, Inc.

HENRY P. BECTON, JR. 3,4,5
Vice Chairman and Former President — WGBH Foundation

CATHERINE M. BURZIK 1,5
Former President and Chief Executive Officer — Kinetic Concepts, Inc.

EDWARD F. DEGRAAN 2,3
Retired Vice Chairman — Gillette of the Procter & Gamble Company

VINCENT A. FORLENZA 4
Chairman, Chief Executive Officer and President

CLAIRE M. FRASER, PH.D. 3,5
Director — Institute for Genome Sciences, University of Maryland School of Medicine

CHRISTOPHER JONES 1,4,5
Retired Chief Executive Officer — JWT Worldwide

MARSHALL O. LARSEN 2,3,4
Retired Chairman, President and Chief Executive Officer — Goodrich Corporation

GARY A. MECKLENBURG 2,3
Retired President and Chief Executive Officer — Northwestern Memorial HealthCare

JAMES F. ORR 2,3
Retired Chairman and Chief Executive Officer — Convergys Corporation

WILLARD J. OVERLOCK, JR. 1,4,5
Retired Partner — Goldman, Sachs & Company

CLAIRE POMEROY, M.D. 3,5
President — The Albert and Mary Lasker Foundation

REBECCA W. RIMEL 3,5
President and Chief Executive Officer — The Pew Charitable Trusts

BERTRAM L. SCOTT 1,2
Senior Vice President of Population Health — Novant Health

Committees appointed by the Board of Directors

1 Audit Committee
2 Compensation and Management Development Committee
3 Corporate Governance and Nominating Committee
4 Executive Committee
5 Science, Marketing, Innovation and Technology Committee
BD is a leading medical technology company that partners with customers and stakeholders to address many of the world’s most pressing and evolving health needs.

**OUR PURPOSE:**
Advancing the world of health

**OUR FOCUS:**
- Enabling safer, simpler and more effective drug delivery
- Improving outcomes through more accurate, timely and efficient diagnostics
- Providing tools and technologies that facilitate the understanding, development and delivery of innovative drug therapies
- Enhancing disease management in diabetes, women’s health and cancer, and infection control
- Advancing clinical, laboratory and research practices in emerging markets

In 2015, BD welcomed CareFusion and its products into the BD family of solutions. For more information on BD, please visit www.bd.com.

**OUR PURPOSE:**
Advancing the world of health

**MORE THAN:**
45,000
ASSOCIATES SERVING
190+
COUNTRIES

**45,000**
ASSOCIATES SERVING
MORE THAN
120,300 gal
WASTEWATER FLOW SAVED
8,053 lbs
SOLID WASTE NOT GENERATED
22,181 lbs
GREENHOUSE GASES PREVENTED
11,500,000 BTUs
ENERGY NOT CONSUMED

**PRINTING INFORMATION**
BD saved the following resources by using 25,736 pounds of Reincarnation Silk 100, made with an average of 100% recycled fiber and an average of 100% post-consumer waste. It is designated Ancient Forest Friendly™ and manufactured with electricity that is offset with Green-e® certified renewable energy certificates.

For information about BD’s Sustainability Program and our 2020 Sustainability Goals, please visit www.bd.com/sustainability2014.

**PRINTING INFORMATION**
Source: Calculations based on research by Environmental Defense Fund and other members of the Paper Task Force.